Brief: Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
24/06/2025 13:01
June 24 (Reuters) - Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS AND CYCLOTEK SIGN CLINICAL SUPPLY AGREEMENT FOR ¹⁶¹TB-KLK3-MAB PHASE I CLINICAL TRIAL IN AUSTRALIA RADIOPHARM THERANOSTICS LTD - PHASE 1 CLINICAL TRIAL IN PROSTATE CANCER ANTICIPATED IN 2H 2025 Source text: ID:nGNX9g9vt8 Further company coverage: RAD.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%